ACCESS Health International, a non-profit think tank, focuses on improving access to high-quality, affordable healthcare globally through research, policy advocacy, and evidence-based action aimed at health systems strengthening.
Founded in 2007 by Prof. William A. Haseltine following his study of healthcare innovations in India, ACCESS Health was established to capture and share key learnings from these models.
We work with governments, healthcare providers, academia, and private organizations to drive health sector improvements. As a 501(c)(3) charity, we are committed to social impact, fostering partnerships that deliver sustainable healthcare solutions. With offices in India, Southeast Asia, MENA, and the United States, we advance healthcare through research, capacity building, and convening networks to support vulnerable communities and strengthen health systems worldwide.
The Stop Hep Alliance is a global collective of organizations and individuals dedicated to the fight against viral hepatitis. With the shared goal of eliminating viral hepatitis as a public health threat by 2030, At the heart of the Stop Hep Alliance is a commitment to comprehensive strategies that address the prevention, diagnosis, treatment, and care of viral hepatitis. We believe that through a multi-pronged approach, including policy advocacy, community engagement, strategies implementation and innovative interventions, we can make a significant impact in reducing the burden of viral hepatitis worldwide.
Strategic Partnership with The Hepatitis Fund (THF) : Key Achievement:
Grant accepted for an AI-Driven Platform to design a comprehensive AI-powered solution for:
1. Hepatitis data collection and integration
2. Predictive modelling and burden estimation
3. AI-based decision-making support for national programs aligned with global hepatitis elimination goals by 2030 through data-driven strategies.
Regional-Level Engagement:
Close collaboration with the Institute of Virology, Uzbekistan, supporting national hepatitis elimination planning and implementation.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close